Sanome has been named Most Innovative Biomarker Platform 2023 by the Global Health & Pharma Awards, within the International Life Sciences Awards category.
Sanome had the honour of being shortlisted for the prestigious International Life Sciences Awards earlier this year. Following a comprehensive and rigorous evaluation and assessment process, we have been distinguished as the Most Innovative Biomarker Platform of 2023, worldwide. This commendation and recognition, as conferred by a distinguished panel of our peers and judges from the life sciences domain, signifies a milestone in our academic and commercial journey. It endorses our shared commitment to innovation and excellence in the realm of biomarker research and application.
We are hugely grateful to our collaborators – the clinical, research, and commercial partners, advisors, and investors who have supported us along the way. An integral part of our journey, believing in our mission and contributing significantly to the development of our biomarker platform and long term human digital twin vision. This recognition is a shared award and we look forward to what we can continue achieving together. We remain committed to our mission and look forward to using this positive recognition to further our contributions to the life sciences sector as we move to change healthcare for all.
Sanome’s Founder & CEO Benedikt von Thüngen commented:
“I am in shock. Also delighted! For a small startup this is huge validation of our work and the ambition we have to change healthcare. This award is testament to the incredible work that the team at Sanome are committing to developing our solution. I truly believe that what we are building is going to transform healthcare infrastructure into proactive, cost-effective, inviolable and preventative systems. Through biomarkers; gathered from our external environments both past and present, and those millions of unique constantly changing biological indicators which can be measured, we can create a system which circumvents and instantly detects changes to our individual state. Acting sooner saves lives. That’s what we’re ultimately here to do at Sanome. “
Paul Aykroyd, Sanome’s COO added:
“We’ve had a hugely exciting year so far; deploying pilots in hospitals, co-designing with clinicians and patient representatives, growing the team and as a team; so this recognition from the nomination through to the judges decision and voting is a great opportunity to reflect on our growth and where we’re going. I have loved working with this team – their passion is infectious and intelligence next level.”
Olivia Buckland, summarised the sentiment of the Sanome team:
“To be recognised as THE global innovator in our domain amongst incredible innovators and technology is hugely gratifying and motivating . This startup is driven by the passion of the team and pure gritty determination to make our vision a reality. We can’t wait to continue growing and developing life-saving insights and solutions.”
ABOUT THE AWARDS – by Global Health & Pharma Magazine (GHP)
“GHP Magazine has announced the winners of the International Life Sciences Awards 2023.
Operating in an industry rife with cutting-edge technologies, scientific advancements, and evolving regulatory requirements, life sciences companies are constantly working to keep up with new developments and stay ahead of their competitors. In this, innovation is at the forefront of their minds. Their breakthrough discoveries can impact the lives of patients across the world by facilitating the development of novel products and treatments.
The last few years have revealed the true resilience and strength of the life sciences industry as it faced the Covid-19 pandemic head on. Whilst we have now returned to normalcy in 2023, the effects of the recent years are still fresh in our minds. We have not forgotten the role our key healthcare businesses and organisations played in enabling us to reach the other side of the pandemic.
GHP magazine, as always, endeavours to recognise those that are going above and beyond, or indeed, the businesses that are making meaningful steps forward, no matter how small they might seem on the greater landscape. That’s why we launched our awards programme, and why we continue to spotlight the work of exceptional companies and individuals.
Awards Co-ordinator, Laura O’Carroll, commented on the success of these excellent winners: “We are delighted to announce the publication of our International Life Sciences Awards programme for the eighth consecutive year. I offer my sincere congratulations to all of our winners and wish them the best of luck in the years to come.” “
NOTES TO EDITORS
Founded in 2021, Sanome is developing novel AI to translate hospital data into clinically-actionable insights and early warning systems to predict individual health & recovery outcomes enabling clinical teams act earlier than currently possible.
Sanome’s cutting edge technology additionally bridges the translational gap between clinical innovation and clinical practice. The company’s long-term goal is to build a human digital twin for all to have proactive and affordable oversight for individual health. Sanome is currently working with private hospitals, healthcare providers, and NHS Trusts across the United Kingdom.
About GHP Magazine
Global Health & Pharma Magazine (GHP) was initially launched to act as an information sharing platform for those in the healthcare and pharmaceutical industries. Though it maintains this founding cornerstone, the magazine itself, with a global circulation, has expanded in scope to magnify the work of those that are setting the pace and looking to change their respective sectors for the better.
Each year these awards celebrate the wide scope of excellence shown across the global Life Sciences industry. Global Health & Pharma utilises this awards programme to highlight worthy companies who have excelled in their respective fields. Standing out amongst the competition is an important factor for consideration. As with all awards programmes within Global Health & Pharma’s repertoire, the International Life Sciences Awards takes a merit-based approach towards assessment which ensures each nominee receives equal attention. We can proudly state that all nominees, from start-ups and small companies to international firms, are treated fairly. Our unbiased research techniques work alongside third-party nominations and self-submissions.